N-(4-chlorophenyl)-1-methylpiperidin-4-amine | 36796-53-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(4-chlorophenyl)-1-methylpiperidin-4-amine
• CAS: 36796-53-9
• 化学式: C₁₂H₁₇ClN₂
• mdl: MFCD01653850
• 分子量: 224.733
• InChiKey: VTAXYNRMXBENDI-UHFFFAOYSA-N

物化性质

• 溶解度：
  30.6 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-chlorophenyl)-1-methylpiperidin-4-amine 在 sodium hydroxide 、 sodium tetrahydroborate 、 三氯化硼 作用下， 以 1,4-二氧六环 、 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 5.0h， 生成 ethyl 4-(5-chloroindol-1-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  Sasakura, Kazuyuki; Adachi, Makoto; Sugasawa, Tsutomu, Synthetic Communications, 1988, vol. 18, # 3, p. 265 - 274

  摘要：

  DOI：
• 作为产物：
  描述：

  对氯苯胺 在 sodium tetrahydroborate 、 4 A molecular sieve 、 对甲苯磺酸 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 9.0h， 生成 N-(4-chlorophenyl)-1-methylpiperidin-4-amine
  参考文献：
  名称：

  Structure-Activity Studies of Fentanyl

  摘要：

  报道了在苯环中带有对位取代基，苯甲基与苯基之间以亚甲基或双亚甲基分离的芬太尼类似物的制备，以及苯乙酰取代丙酰作为N-酰基取代物。虽然检测到的所有对位取代基都降低了大鼠的抗痛觉效力，但这种类似物中的大多数比吗啡更有效，而p-F、I和Me衍生物的活性仅比芬太尼低几倍。将苯甲基与苯分离会降低效力，而N-苯乙基类似物保持合理的活性（>吗啡）。所有苯乙酰类似物的效力都很低或无效。附加了可能遇到的“设计药物”的类似物的质谱诊断细节。

  DOI：

  10.1111/j.2042-7158.1988.tb05318.x

文献信息

• [EN] PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER<br/>[FR] DÉRIVÉS PIPÉRIDINE ET PIPÉRAZINE ET LEUR UTILISATION POUR TRAITER LES INFECTIONS VIRALES ET LE CANCER
  申请人：US HEALTH

  公开号：WO2015080949A1

  公开（公告）日：2015-06-04

  Disclosed are compounds of formula (I) (formula I),as antiviral agents, antineoplastic agents, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X and Y are independently CH or N, o is 0, 1 or 2, and E is absent or is (CR13 R14 )m, NH, or S, F is absent or is (CR15 R16 )n, C=O, or -SO2 -, G is absent or is (CR17 CR18 )r, H is absent or is C=O, or -SO2 - and R1, Ar1, Ar2 are as defined in the specification. These compounds are antiviral agents and are contemplated in the treatment of viral infections, for example, hepatitis C, or are antineoplastic agents.

  揭示了化合物的结构式（I）（式I），作为抗病毒剂、抗肿瘤剂，包括这些化合物的药物组合物，以及这些化合物的使用方法，其中X和Y分别为CH或N，o为0、1或2，E不存在或为（CR13 R14）m、NH或S，F不存在或为（CR15 R16）n、C=O或-SO2-，G不存在或为（CR17 CR18）r，H不存在或为C=O或-SO2-，R1、Ar1、Ar2如规范中所定义。这些化合物是抗病毒剂，可用于治疗病毒感染，例如丙型肝炎，或作为抗肿瘤剂。
• 1,4-Benzodiazepine derivatives
  申请人：Shionogi & Co., Ltd.

  公开号：US04560684A1

  公开（公告）日：1985-12-24

  1,4-Benzodiazepine derivatives of the formula: ##STR1## (in which R.sup.1 is pyrrolidinyl or piperidinyl each optionally substituted by C.sub.1-3 alkyl, phenyl-C.sub.1-3 alkyl, C.sub.1-5 alkanoyl, or C.sub.2-5 alkoxycarbonyl, R.sup.2 is hydrogen, hydroxy, or acetoxy, R.sup.3 is C.sub.1-3 alkyl, phenyl-C.sub.1-3 alkyl, or phenyl optionally substituted by one or two halogens, X is hydrogen, halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, nitro, trifluoromethyl, or di-C.sub.1-3 alkyl-amino, and n is 1 or 2) or pharmaceutically acceptable acid addition salts thereof, which are useful as a psychotropic agent such as anti-depressant or anxiolytic agent can be prepared from several routes.

  公式为1,4-苯二氮平衍生物：##STR1##（其中R.sup.1是吡咯烷基或哌嗪基，每个基团可选择地被C.sub.1-3烷基，苯基-C.sub.1-3烷基，C.sub.1-5 醇酰基或C.sub.2-5 烷氧羰基取代，R.sup.2是氢，羟基或乙酰氧基，R.sup.3是C.sub.1-3烷基，苯基-C.sub.1-3烷基或苯基，可选择地被一个或两个卤素取代，X是氢，卤素，C.sub.1-3烷基，C.sub.1-3烷氧基，硝基，三氟甲基或二C.sub.1-3烷基氨基，n为1或2）或其药物可接受的酸加合物，可用多种方法制备，用作精神药物如抗抑郁或抗焦虑剂。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070161641A1

  公开（公告）日：2007-07-12

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地与多巴胺D3受体结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括对患者进行治疗，向患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及所述化合物的制备过程，以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1935887A1

  公开（公告）日：2008-06-25

  The invention relates to heterocyclic substituted carbonyl derivatives of the formula I that display selective binding to dopamine D3 receptors and are useful for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

  本发明涉及式 I 的杂环取代的羰基衍生物 本发明涉及式 I 的杂环取代羰基衍生物，该衍生物与多巴胺 D3 受体具有选择性结合，可用于治疗需要此类治疗的患者中与多巴胺 D3 受体活性相关的中枢神经系统紊乱，包括向受试者施用治疗有效量的所述化合物以缓解此类紊乱。可用这些化合物治疗的中枢神经系统疾病包括精神障碍、药物依赖、药物滥用、运动障碍（如帕金森病、帕金森氏症、神经抑制剂诱发的迟发性运动障碍、吉勒-德拉图雷特综合征和亨廷顿氏病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及本文所述化合物的制备过程以及将这些化合物用作多巴胺 D3 受体成像剂的制备和使用方法。